長春高新(000661.SZ):鼻噴減毒流感疫苗投產時間延期至2020年6月
格隆匯12月12日丨長春高新(000661.SZ)公佈,此次擬延期投產的募集資金投資項目為公司子公司——長春百克生物科技股份公司(“百克生物”)疫苗生產基地I期項目。該項目由百克生物組織實施,擬建設鼻噴減毒流感疫苗、新型狂犬疫苗、新型百白破聯合疫苗生產基地,項目原計劃2018年投產。
經公司於2019年3月5日召開的第九屆董事會第五次會議審議通過的《關於部分募集資金投資項目投產延期的議案》,受藥品生產批件以及研發及新藥技術審評等原因,公司將項目中的鼻噴減毒流感疫苗的投產時間延期至2019年9月,新型狂犬病疫苗的投產時間延期至2020年12月,新型百白破聯合疫苗的投產時間延期至2022年12月。
截至 2019年11月30日,該項目主體工程已基本完工,其中鼻噴減毒流感疫苗已經完成了生產註冊以及GMP認證現場檢查等工作。
鑑於鼻噴減毒流感疫苗生產批件正處於國家藥品監督管理部門審批階段,同時考慮到世界衞生組織流感疫苗毒株發放時間和流感疫苗季節性銷售的特點,公司決定將項目中鼻噴減毒流感疫苗投產時間延期至2020年6月,新型狂犬病疫苗和新型百白破聯合疫苗預計投產時間無變化。
此次募集資金投資項目部分產品的延期投產,是公司根據項目的實施進展以及在不影響公司正常生產經營的情況下作出的審慎決定。此次項目部分產品延期投產未改變該項目的實施主體、實施方式以及主要投資內容,不存在變相改變募集資金投向和損害其他股東利益的情形,也不會對公司的正常經營產生不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.